



# Bal Pharma Limited

To,  
The Manager-Listing  
National Stock Exchange of India Ltd  
Mumbai.

01.07.2021

BSE Limited  
Mumbai.

Dear Sir,

Sub : Press Release.  
Ref : Regulation 30 of SEBI(LODR) Regulations.

With reference to the above, we would like to bring to the notice of the exchange that we are releasing the enclosed press release to the media , on the financial performance of the Company .

Please take the same on record.

Thanking You.

For Bal Pharma Limited

Authorised Signatory.



# Bal Pharma Limited

## BAL Pharma Limited returns to its profitable performance

Reports 45% Revenue growth in FY2021.

**July 1, 2021, Bengaluru:** BAL Pharma Limited recorded a revenue of INR 252 Cr for FY2021 compared to revenue of INR 174 Cr in FY2020, registering growth of 81% on a standalone basis. EBITDA (Earnings Before Interest Depreciation and Taxes) was reported at INR 29.2 cr. The Company returned to its profitable performance and reported a net profit of INR 9.22 Cr versus a net loss of INR 9 Cr in FY20. The Board of directors has recommended a final dividend of INR 1 per equity share.

All in INR Crores			
Particulars	FY21	FY20	YoY
Sales	245.7	167.3	47%
API	129.7	71.5	81%
API Domestic	56.1	25.2	123%
API Exports	73.6	46.4	59%
Formulations	116.1	95.7	21%
Formulations Domestic	29.4	38.9	-24%
Formulations Exports	86.6	56.8	53%
EBITDA	29.2	10.50	N.A
PAT	9.22	-8.90	N.A

### Financial Highlights

- Revenue- Strong contribution from Export business registering growth of 55% YoY. Export growth was led by both API and Formulations segments. API: Formulation mix for FY21 stood at 53:47 versus 43:57 in FY20.
- API segment reported growth of 81% YoY led by strong Domestic business. Domestic API's grew by robust 123% YoY, led by its Anti Diabetic drug.

Formulations reported growth of 21% led by higher export Sales . Overall good momentum in the international markets aided by strong performance in various territories across the world .

**CORPORATE OFFICE :** 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

**Ph. :** 91 - 80 - 41379500 **Fax :** 91 - 80 - 22354057 / 58

**Email :** [info@balpharma.com](mailto:info@balpharma.com) **Website :** [www.balpharma.com](http://www.balpharma.com)

**CIN #** L85110KA1987PLC008368

**REGD. OFFICE & FACTORY :** 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. **Ph. :** 41570813 / 19 **Fax :** 41570820



# Bal Pharma Limited

- EBITDA margins were marginally affected due to higher Raw material prices especially of N AMINO AND PARACETAMOL.
- Order book position of the Company up to 30.09.2021 stands at Rs.70.00 Cr with API's contributing to Rs.45 Cr and formulations at Rs.25 Cr.

Commenting on financial results, Mr. Shailesh Siroya, Managing Director, BAL Pharma said, "The financial performance for FY21 has been encouraging in one of the most challenging periods in recent history. We are pleased with the strength showcased by all our business units – with the Export business recording higher growth for the year Our international formulations business has performed well and shows great promise with a focused growth strategy for our key markets, aided by new launches. On API front Domestic markets were quite buoyant and has witnessed significant improvement over previous year. Overall, medium to long-term growth opportunities are encouraging and various cost efficiency initiatives instituted over the last year places us well to enhance value for all our key stakeholders."

**For more information, contact,**

Mr.Y.Venu Madhava Reddy on

Phone : 080 41379538

Email : venu@balpharma.com

---

**CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India**

**Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58**

**Email : info@balpharma.com Website : www.balpharma.com**

**CIN # L85110KA1987PLC008368**

**REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820**